| Title | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. | | Author(s) | Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM | | Institution | Department of Medical Oncology, Clínica Universitaria de Navarra, Pamplona, Spain, ynieto@mdanderson.org. | | Source | Cancer Chemother Pharmacol 2009 Jun 14. | | Abstract | PURPOSE: Capecitabine is effective against metastatic breast cancer (MBC). We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting.
METHODS: In this prospective phase II clinical trial patients with HER2-negative and node-positive or locally advanced tumors were eligible to receive four cycles of EC (100/600 mg/m(2)) every 2 weeks with G-CSF on days 3-10, followed by four cycles of docetaxel/capecitabine (75/1,000 mg/m(2) b.i.d., days 1-14) every 3 weeks.
RESULTS: Fifty-five patients were enrolled with median age of 49, and 80% had hormone receptor-positive disease. The median tumor size was 2.5 cm, with a median of two axillary nodes involved. Seventy-five percent of the first 20 patients had grade 2/3 hand-foot syndrome (HFS). Dose reduction of capecitabine to 800 mg/m(2) reduced the grade 2/3 HFS incidence to 31% in the remaining patients. No grade 4/5 toxicities were observed. All 20 patients treated preoperatively responded, with 5 (25%) pathologic complete responses and 3 additional pT(0)N(1) tumors. At a median follow-up of 48 (range 28-60) months, the event-free and overall survival rates are 91 and 98%, respectively.
CONCLUSIONS: Sequential treatment with dose-dense EC followed by docetaxel/capecitabine, using a lower capecitabine dose than that approved for MBC, has an acceptable toxicity profile and encouraging activity when used as neoadjuvant or adjuvant treatment of breast cancer. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19526361 |
|
